Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 3. fázisFut, nem toborozSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Where
- Baoding, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Ha’erbin, Hangzhou, Hebei, Hefei, Jiamusi, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Suzhou, Taiyuan, Wanzhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhejiang, Zhengzhou
- Életkor
- 18 év and over
- People
- 621 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00 - 1. fázisTaking peopleHS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Hangzhou Huasai Biomedicine Co., Ltd.
See details and how to joinNCT07105176 - 2. fázisTaking peopleA Study of YL202 in Patients With Advanced Solid Tumors
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 100
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07202364 - 1. fázisTaking peopleA Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Hangzhou Huasai Biomedicine Co., Ltd.
See details and how to joinNCT07830342 - No phaseNot yet taking people in KínaMRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT07873086 - 2. fázisNot yet taking people in KínaProspective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 256
- Run by
- Sun Yat-sen University
See details and how to joinNCT07874464 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 1/2. fázisTaking peoplePhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- Beijing, Jinan, Shanghai, Suzhou
- Életkor
- 18 év and over
- People
- 554 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - 1. fázisTaking peopleSafety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 167
- Run by
- Shandong Boan Biotechnology Co., Ltd
See details and how to joinNCT06596915 - 2. fázisTaking peopleDelayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT06778382 - 2. fázisTaking peopleTislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 34
- Run by
- Qilu Hospital of Shandong University
See details and how to joinNCT07089199 - No phaseTaking peopleCAIX-targeted PET/CT in Solid Tumors
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 100
- Run by
- Zhongnan Hospital
See details and how to joinNCT07833085 - 2. fázisNot yet taking people in KínaA Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
- Where
- Beijing, Changsha Shi, Chengdu, Shanghai
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07871214 - 1/2. fázisTaking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Chongqing, Hangzhou, Tianjin, Wuhan
- Életkor
- 18 év and over
- People
- 1438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - No phaseTaking peopleCHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
- Where
- Chengdu
- Életkor
- 18 év and over
- People
- 590
- Run by
- AstraZeneca
See details and how to joinNCT07413757 - 2. fázisTaking peopleSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Where
- Beijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00 - 3. fázisTaking peopleSRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 340
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06457906 - 3. fázisTaking peopleSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 1410 worldwide
- Run by
- Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01 - 2/3. fázisTaking peopleSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Where
- Guangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- Pfizer
See details and how to joinNCT07226999 · EU 2025-523522-41-00 - 1/2. fázisTaking peopleSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Where
- Beijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan
- Életkor
- 18 év and over
- People
- 162 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00 - 2. fázisTaking peopleSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Where
- Beijing, Guangzhou, Jinan, Shanghai
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00 - 2/3. fázisNot yet taking people in KínaA Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Anyang, Beijing, Chongqing, Dalian, Guangzhou, Harbin, Hefei, Jinan, Nanning, Qingdao, Shijiazhuang, Wuha, Xuzhou, Zhenzhou, Zunyi
- Életkor
- 18 nap to 75 nap
- People
- 1438
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07865910 - 3. fázisTaking peopleNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 290
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07863999 - 1/2. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Where
- Beijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai
- Életkor
- 18 év and over
- People
- 327 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00